Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

Ozempic has been approved for diabetes, though it's sometimes still used for weight loss. Rybelsus is a similar drug that's the same price and uses the same ingredient as Ozempic. But Rybelsus is a ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

The key drugs in the weight-loss injection market are Ozempic, Wegovy and Mounjaro. Understandably, there has been a flurry of interest in knowing more about these drugs – the differences between them ...